Compare IGI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGI | NSPR |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.8M | 81.8M |
| IPO Year | N/A | N/A |
| Metric | IGI | NSPR |
|---|---|---|
| Price | $16.49 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 33.9K | ★ 60.0K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | N/A | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $15.13 | $1.59 |
| 52 Week High | $17.79 | $3.80 |
| Indicator | IGI | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 48.73 |
| Support Level | $16.38 | $1.66 |
| Resistance Level | $16.59 | $2.15 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 66.67 | 52.94 |
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.